IC
AMRX icon

Innealta Capital’s Amneal Pharmaceuticals AMRX Stock Holding History

Innealta Capital’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-847
Closed -$5.38K – 227
2024
Q2 		$5.38K Buy
+847
New +$5.38K ﹤0.01% 912

Other funds holding AMRX

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Innealta Capital's AMRX Position: Q3 2024 in Review

Innealta Capital sold out of Amneal Pharmaceuticals (AMRX) in Q3 2024, closing a stake of 847 shares — an estimated $5.38K sold.

Innealta Capital first reported a position in AMRX in Q2 2024 and held it in 1 quarter. The position peaked at $5.38K in Q2 2024. 182 funds tracked by Wall St. Rank hold AMRX as of Q3 2024.

  • Innealta Capital reported no remaining Amneal Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 847 Amneal Pharmaceuticals shares in Q3 2024, an estimated $5.38K.
  • Innealta Capital first reported a position in Amneal Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Amneal Pharmaceuticals position peaked at $5.38K in Q2 2024.
  • 182 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.